Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Circulating tumor DNA genomics correlate with resistance to abiraterone and enzalutamide in prostate cancer.

Annala M, Vandekerkhove G, Khalaf D, Taavitsainen S, Beja K, Warner EW, Sunderland K, Kollmannsberger C, Eigl BJ, Finch D, Oja CD, Vergidis J, Zulfiqar M, Azad AA, Nykter M, Gleave ME, Wyatt AW, Chi KN.

Cancer Discov. 2018 Jan 24. pii: CD-17-0937. doi: 10.1158/2159-8290.CD-17-0937. [Epub ahead of print]

PMID:
29367197
2.

Immune Modulation by Androgen Deprivation and Radiation Therapy: Implications for Prostate Cancer Immunotherapy.

Kalina JL, Neilson DS, Comber AP, Rauw JM, Alexander AS, Vergidis J, Lum JJ.

Cancers (Basel). 2017 Jan 27;9(2). pii: E13. doi: 10.3390/cancers9020013. Review.

3.

Impact of Weight Changes After the Diagnosis of Stage III Colon Cancer on Survival Outcomes.

Vergidis J, Gresham G, Lim HJ, Renouf DJ, Kennecke HF, Ruan JY, Chang JT, Cheung WY.

Clin Colorectal Cancer. 2016 Mar;15(1):16-23. doi: 10.1016/j.clcc.2015.07.002. Epub 2015 Jul 26.

PMID:
26281943
4.

Cost-effectiveness of therapies for melanoma.

Johnston KM, McPherson E, Osenenko K, Vergidis J, Levy AR, Peacock S.

Expert Rev Pharmacoecon Outcomes Res. 2015 Apr;15(2):229-42. doi: 10.1586/14737167.2015.1017563. Epub 2015 Feb 23. Review.

PMID:
25703441
5.

KHYG-1, a model for the study of enhanced natural killer cell cytotoxicity.

Suck G, Branch DR, Smyth MJ, Miller RG, Vergidis J, Fahim S, Keating A.

Exp Hematol. 2005 Oct;33(10):1160-71.

PMID:
16219538

Supplemental Content

Loading ...
Support Center